Efficacy and safety of CD34-selected and CD19-depleted autografting in multiple myeloma patients: a pilot study.
about
The ex vivo purge of cancer cells using oncolytic viruses: recent advances and clinical implicationsMolecular purging of multiple myeloma cells by ex-vivo culture and retroviral transduction of mobilized-blood CD34+ cells.Reovirus as a successful ex vivo purging modality for multiple myeloma.Selective purging of human multiple myeloma cells from autologous stem cell transplantation grafts using oncolytic myxoma virus.
P2860
Efficacy and safety of CD34-selected and CD19-depleted autografting in multiple myeloma patients: a pilot study.
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Efficacy and safety of CD34-se ...... eloma patients: a pilot study.
@ast
Efficacy and safety of CD34-se ...... eloma patients: a pilot study.
@en
type
label
Efficacy and safety of CD34-se ...... eloma patients: a pilot study.
@ast
Efficacy and safety of CD34-se ...... eloma patients: a pilot study.
@en
prefLabel
Efficacy and safety of CD34-se ...... eloma patients: a pilot study.
@ast
Efficacy and safety of CD34-se ...... eloma patients: a pilot study.
@en
P2093
P1476
Efficacy and safety of CD34-se ...... eloma patients: a pilot study.
@en
P2093
Bosse Björkstrand
Eva Gaarsdal
Heidi Andersen
Thomas Rasmussen
P356
10.1016/S0301-472X(01)00758-5
P577
2002-01-01T00:00:00Z